With the number of biosimilar products steadily increasing, pharmacists play a central role in ensuring their appropriate use in inflammatory conditions. This episode highlights approval pathways, interchangeability, and real-world challenges pharmacists may face when integrating biosimilars into care plans. You will walk away better prepared to support prescribers, counsel patients, and contribute to cost-effective, evidence-informed therapy decisions.
HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls
GUEST
Reemal Zaheer, PharmD, CSP
Pharmacist
Johns Hopkins Medicine
Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only
To learn more about Health Mart, click here: https://join.healthmart.com/
CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Explain the role of biosimilars in the treatment of inflammatory conditions.
2. Describe considerations for the pharmacist when evaluating or counseling on biosimilar therapies.
Rachel Maynard and Reemal Zaheer have no relevant financial relationships with ineligible companies to disclose.
0.075 CEU/0.75 Hr
UAN: 0107-0000-26-045-H01-P
Initial release date: 2/2/2026
Expiration date: 2/2/2027
Additional CPE details can be found here.
